Skip to content

Press Releases

Updates on ProBioGen and currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines. 

ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology

Berlin, Germany, March 7, 2022 MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy..

Read More

ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology

Berlin, Germany, February 11, 2022: ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology. Following evaluation of the..

Read More

ProBioGen announces Innovent as a new Partner signing License of GlymaxX® Technology

Berlin, Germany, January 11, 2022: ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology. Under..

Read More

Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

Berlin, Germany and New York, USA, January 6, 2022: ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq..

Read More

ProBioGen's GlymaxX® Technology reaches Phase III Clinical Development

Berlin, December 17, 2021: ProBioGen AG, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for..

Read More

ProBioGen's GlymaxX® Technology made it again into Clinical Phase I

Berlin, November 17, 2021: ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another..

Read More

PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development

Barcelona, Spain, November 3, 2021: ProBioGen is delighted to announce that today, its Chief Scientific Officer Dr. Volker Sandig has presented at 13th annual PEGS Europe Protein..

Read More

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

Mar 6, 2025

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio

Feb 4, 2025

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth

Jan 7, 2025

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Change in Management

Apr 30, 2024

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever

Mar 27, 2024

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

Mar 13, 2024

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology

Dec 14, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Sep 26, 2023

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™

May 17, 2023

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

May 4, 2023

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

Apr 12, 2023

ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023

Mar 30, 2023

ProBioGen’s Growth Strategy Continues Successfully

Mar 2, 2023

Press Contact

probiogen-sarah-wandrey

Sarah Wandrey

Corporate Communications

Phone: +49 (0) 30 3229 35 144
Email: press@probiogen.de

ProBioGen News 

Join our news and always be up-to-date.